Long‐term outcome of clozapine use for psychosis in parkinsonian patients
Identifieur interne : 005623 ( Main/Merge ); précédent : 005622; suivant : 005624Long‐term outcome of clozapine use for psychosis in parkinsonian patients
Auteurs : Hubert H. Fernandez [États-Unis] ; Edward M. Donnelly [États-Unis] ; Joseph H. Friedman [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-07.
English descriptors
- KwdEn :
- Aged, Antipsychotic Agents (administration & dosage), Antipsychotic Agents (therapeutic use), Clozapine (administration & dosage), Clozapine (therapeutic use), Cohort Studies, Female, Humans, Male, Parkinson Disease (complications), Parkinson Disease (epidemiology), Parkinson's disease, Psychotic Disorders (complications), Psychotic Disorders (drug therapy), Psychotic Disorders (epidemiology), Retrospective Studies, Time, clozapine, drug‐induced psychosis, long‐term efficacy.
- MESH :
- chemical , administration & dosage : Antipsychotic Agents, Clozapine.
- chemical , therapeutic use : Antipsychotic Agents, Clozapine.
- complications : Parkinson Disease, Psychotic Disorders.
- drug therapy : Psychotic Disorders.
- epidemiology : Parkinson Disease, Psychotic Disorders.
- Aged, Cohort Studies, Female, Humans, Male, Retrospective Studies, Time.
Abstract
A retrospective analysis was carried out on 39 parkinsonian patients on clozapine treatment ≥24 months for psychosis. The cohort had a mean age of 76 years and an average clozapine dose of 47 mg/day over 60 months of clozapine use. Of 39 patients, 13 (33%) patients were eventually admitted to nursing homes, 6 (46%) of whom died over a period of 5 years. The overall 5‐year mortality rate in this cohort was 44% (17/39). Of 39 patients, 33 (85%) had continued partial/good response and 5 (13%) had complete resolution of psychosis. None discontinued clozapine due to motor worsening. Among patients who responded early on, the long‐term efficacy of clozapine for psychosis was sustained. The risk of nursing home placement and mortality among parkinsonian patients treated with clozapine for psychosis in this geriatric cohort was better than that reported previously. Our data are more consistent with recently published long‐term outcome data suggesting an improvement in the prognosis of parkinsonian patients with psychosis with the use of atypical antipsychotic agents such as clozapine. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20051
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000965
- to stream Istex, to step Curation: 000965
- to stream Istex, to step Checkpoint: 002646
- to stream PubMed, to step Corpus: 003407
- to stream PubMed, to step Curation: 003407
- to stream PubMed, to step Checkpoint: 003417
- to stream Ncbi, to step Merge: 000E77
- to stream Ncbi, to step Curation: 000E77
- to stream Ncbi, to step Checkpoint: 000E77
Links to Exploration step
ISTEX:38CA1687045916EC0F371F96C32A0201C069E9ADLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term outcome of clozapine use for psychosis in parkinsonian patients</title><author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name></author><author><name sortKey="Donnelly, Edward M" sort="Donnelly, Edward M" uniqKey="Donnelly E" first="Edward M." last="Donnelly">Edward M. Donnelly</name></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:38CA1687045916EC0F371F96C32A0201C069E9AD</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20051</idno><idno type="url">https://api.istex.fr/document/38CA1687045916EC0F371F96C32A0201C069E9AD/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000965</idno><idno type="wicri:Area/Istex/Curation">000965</idno><idno type="wicri:Area/Istex/Checkpoint">002646</idno><idno type="wicri:doubleKey">0885-3185:2004:Fernandez H:long:term:outcome</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15254945</idno><idno type="wicri:Area/PubMed/Corpus">003407</idno><idno type="wicri:Area/PubMed/Curation">003407</idno><idno type="wicri:Area/PubMed/Checkpoint">003417</idno><idno type="wicri:Area/Ncbi/Merge">000E77</idno><idno type="wicri:Area/Ncbi/Curation">000E77</idno><idno type="wicri:Area/Ncbi/Checkpoint">000E77</idno><idno type="wicri:doubleKey">0885-3185:2004:Fernandez H:long:term:outcome</idno><idno type="wicri:Area/Main/Merge">005623</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term outcome of clozapine use for psychosis in parkinsonian patients</title><author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Neurosciences, Brown Uniersity School of Medicine, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Donnelly, Edward M" sort="Donnelly, Edward M" uniqKey="Donnelly E" first="Edward M." last="Donnelly">Edward M. Donnelly</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Neurosciences, Brown Uniersity School of Medicine, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Neurosciences, Brown Uniersity School of Medicine, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-07">2004-07</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="831">831</biblScope><biblScope unit="page" to="833">833</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">38CA1687045916EC0F371F96C32A0201C069E9AD</idno><idno type="DOI">10.1002/mds.20051</idno><idno type="ArticleID">MDS20051</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antipsychotic Agents (administration & dosage)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Clozapine (administration & dosage)</term><term>Clozapine (therapeutic use)</term><term>Cohort Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson's disease</term><term>Psychotic Disorders (complications)</term><term>Psychotic Disorders (drug therapy)</term><term>Psychotic Disorders (epidemiology)</term><term>Retrospective Studies</term><term>Time</term><term>clozapine</term><term>drug‐induced psychosis</term><term>long‐term efficacy</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antipsychotic Agents</term><term>Clozapine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term><term>Clozapine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cohort Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Retrospective Studies</term><term>Time</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A retrospective analysis was carried out on 39 parkinsonian patients on clozapine treatment ≥24 months for psychosis. The cohort had a mean age of 76 years and an average clozapine dose of 47 mg/day over 60 months of clozapine use. Of 39 patients, 13 (33%) patients were eventually admitted to nursing homes, 6 (46%) of whom died over a period of 5 years. The overall 5‐year mortality rate in this cohort was 44% (17/39). Of 39 patients, 33 (85%) had continued partial/good response and 5 (13%) had complete resolution of psychosis. None discontinued clozapine due to motor worsening. Among patients who responded early on, the long‐term efficacy of clozapine for psychosis was sustained. The risk of nursing home placement and mortality among parkinsonian patients treated with clozapine for psychosis in this geriatric cohort was better than that reported previously. Our data are more consistent with recently published long‐term outcome data suggesting an improvement in the prognosis of parkinsonian patients with psychosis with the use of atypical antipsychotic agents such as clozapine. © 2004 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.20051"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term outcome of clozapine use for psychosis in parkinsonian patients</title><author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name></author><author><name sortKey="Donnelly, Edward M" sort="Donnelly, Edward M" uniqKey="Donnelly E" first="Edward M." last="Donnelly">Edward M. Donnelly</name></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:38CA1687045916EC0F371F96C32A0201C069E9AD</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20051</idno><idno type="url">https://api.istex.fr/document/38CA1687045916EC0F371F96C32A0201C069E9AD/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000965</idno><idno type="wicri:Area/Istex/Curation">000965</idno><idno type="wicri:Area/Istex/Checkpoint">002646</idno><idno type="wicri:doubleKey">0885-3185:2004:Fernandez H:long:term:outcome</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term outcome of clozapine use for psychosis in parkinsonian patients</title><author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Neurosciences, Brown Uniersity School of Medicine, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Donnelly, Edward M" sort="Donnelly, Edward M" uniqKey="Donnelly E" first="Edward M." last="Donnelly">Edward M. Donnelly</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Neurosciences, Brown Uniersity School of Medicine, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Neurosciences, Brown Uniersity School of Medicine, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-07">2004-07</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="831">831</biblScope><biblScope unit="page" to="833">833</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">38CA1687045916EC0F371F96C32A0201C069E9AD</idno><idno type="DOI">10.1002/mds.20051</idno><idno type="ArticleID">MDS20051</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>clozapine</term><term>drug‐induced psychosis</term><term>long‐term efficacy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A retrospective analysis was carried out on 39 parkinsonian patients on clozapine treatment ≥24 months for psychosis. The cohort had a mean age of 76 years and an average clozapine dose of 47 mg/day over 60 months of clozapine use. Of 39 patients, 13 (33%) patients were eventually admitted to nursing homes, 6 (46%) of whom died over a period of 5 years. The overall 5‐year mortality rate in this cohort was 44% (17/39). Of 39 patients, 33 (85%) had continued partial/good response and 5 (13%) had complete resolution of psychosis. None discontinued clozapine due to motor worsening. Among patients who responded early on, the long‐term efficacy of clozapine for psychosis was sustained. The risk of nursing home placement and mortality among parkinsonian patients treated with clozapine for psychosis in this geriatric cohort was better than that reported previously. Our data are more consistent with recently published long‐term outcome data suggesting an improvement in the prognosis of parkinsonian patients with psychosis with the use of atypical antipsychotic agents such as clozapine. © 2004 Movement Disorder Society</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term outcome of clozapine use for psychosis in parkinsonian patients.</title><author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H" last="Fernandez">Hubert H. Fernandez</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Neurosciences, Brown Uniersity School of Medicine, Providence, Rhode Island, USA. fernandez@neurology.ufl.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Neurosciences, Brown Uniersity School of Medicine, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Donnelly, Edward M" sort="Donnelly, Edward M" uniqKey="Donnelly E" first="Edward M" last="Donnelly">Edward M. Donnelly</name></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H" last="Friedman">Joseph H. Friedman</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15254945</idno><idno type="pmid">15254945</idno><idno type="doi">10.1002/mds.20051</idno><idno type="wicri:Area/PubMed/Corpus">003407</idno><idno type="wicri:Area/PubMed/Curation">003407</idno><idno type="wicri:Area/PubMed/Checkpoint">003417</idno><idno type="wicri:Area/Ncbi/Merge">000E77</idno><idno type="wicri:Area/Ncbi/Curation">000E77</idno><idno type="wicri:Area/Ncbi/Checkpoint">000E77</idno><idno type="wicri:doubleKey">0885-3185:2004:Fernandez H:long:term:outcome</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term outcome of clozapine use for psychosis in parkinsonian patients.</title><author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H" last="Fernandez">Hubert H. Fernandez</name><affiliation wicri:level="2"><nlm:affiliation>Department of Clinical Neurosciences, Brown Uniersity School of Medicine, Providence, Rhode Island, USA. fernandez@neurology.ufl.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Neurosciences, Brown Uniersity School of Medicine, Providence, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Donnelly, Edward M" sort="Donnelly, Edward M" uniqKey="Donnelly E" first="Edward M" last="Donnelly">Edward M. Donnelly</name></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H" last="Friedman">Joseph H. Friedman</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antipsychotic Agents (administration & dosage)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Clozapine (administration & dosage)</term><term>Clozapine (therapeutic use)</term><term>Cohort Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (epidemiology)</term><term>Psychotic Disorders (complications)</term><term>Psychotic Disorders (drug therapy)</term><term>Psychotic Disorders (epidemiology)</term><term>Retrospective Studies</term><term>Time</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antipsychotic Agents</term><term>Clozapine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term><term>Clozapine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cohort Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Retrospective Studies</term><term>Time</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A retrospective analysis was carried out on 39 parkinsonian patients on clozapine treatment >/=24 months for psychosis. The cohort had a mean age of 76 years and an average clozapine dose of 47 mg/day over 60 months of clozapine use. Of 39 patients, 13 (33%) patients were eventually admitted to nursing homes, 6 (46%) of whom died over a period of 5 years. The overall 5-year mortality rate in this cohort was 44% (17/39). Of 39 patients, 33 (85%) had continued partial/good response and 5 (13%) had complete resolution of psychosis. None discontinued clozapine due to motor worsening. Among patients who responded early on, the long-term efficacy of clozapine for psychosis was sustained. The risk of nursing home placement and mortality among parkinsonian patients treated with clozapine for psychosis in this geriatric cohort was better than that reported previously. Our data are more consistent with recently published long-term outcome data suggesting an improvement in the prognosis of parkinsonian patients with psychosis with the use of atypical antipsychotic agents such as clozapine.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005623 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005623 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:38CA1687045916EC0F371F96C32A0201C069E9AD
|texte= Long‐term outcome of clozapine use for psychosis in parkinsonian patients
}}
| This area was generated with Dilib version V0.6.23. |  |